Understanding the role of cFLIP in B cell lymphoma pathogenesis (A05)

破坏B淋巴细胞死亡的突变会导致免疫疾病，包括淋巴结病、脾肿大和B细胞淋巴瘤。CFLIP是一种关键的细胞死亡抑制因子，其高表达常与弥漫性大B细胞淋巴瘤(DLBCL)和霍奇金淋巴瘤(HL)相关，并与肿瘤进展和不良临床预后相关。然而，cFLIP在B细胞生物学和淋巴瘤发生中的确切作用尚不清楚。本项目的主要目的是确定cFlIP在DLBCL的发生和发展中的作用，并确定如何利用其抑制作用来治疗淋巴瘤。

Mutations that impair B lymphocyte death lead to immune disorders, including lymphadenopathy, splenomegaly and B cell lymphoma. cFLIP is a key cell death inhibitor whose elevated expression has been frequently associated with diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL) and correlates with tumor progression and poor clinical outcome. However, the exact role of cFLIP in B-cell biology and lymphomagenesis has not been elucidated, yet. The major objective of this project is to characterize the role of cFLIP in the pathogenesis and progression of DLBCL and determine how its inhibition could be exploited for the treatment of lymphoma.